The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.
Nine men face prosecution for one of Nigeria's deadliest rural attacks in recent years, as authorities seek to demonstrate action on persistent security crises in the volatile Middle Belt region.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
Prime Minister Jonas Gahr Stoere has publicly agreed with Crown Princess Mette-Marit's own assessment that she showed "poor judgement" in maintaining contact with convicted sex offender Jeffrey Epstein. The comments come as newly released court documents reveal extensive email correspondence, adding pressure on the Norwegian monarchy during a period of significant personal and institutional challenges.
Ukrainian President Zelenskiy notes a 24-hour pause in targeted Russian strikes on energy grids, yet civilian casualties mount in frontline regions. The reported lull follows a disputed, short-term truce brokered by the U.S., as both sides prepare for talks in Abu Dhabi.
The military leadership in Guinea-Bissau has freed a key opposition figure and pledged to form an inclusive government, in moves widely seen as an effort to appease regional bloc ECOWAS following November's coup.
A convoy of Syrian government forces was observed moving toward the strategic northeastern city of Hasakah on Monday, implementing a ceasefire agreement that aims to reintegrate Kurdish-administered territories with Damascus.
Steve Wright, the serial killer serving life for the 2006 Ipswich murders, has pleaded guilty to the 1999 kidnapping and murder of 17-year-old Victoria Hall, bringing long-awaited closure to a family and exposing an earlier chapter of his crimes.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Iranian authorities announced the arrest of four foreigners allegedly involved in last month's widespread unrest, seizing homemade explosives in the operation as the government continues to blame external actors for domestic turmoil.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Vice President Sara Duterte faces renewed impeachment efforts in the Philippine Congress, centered on allegations of misusing millions in confidential funds. The move reignites political tensions in a nation grappling with the legacies of powerful political dynasties.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
A bus carrying Ukrainian miners home from their shift was struck by Russian drones in a coordinated attack, leaving at least 15 dead and 7 wounded. The assault, condemned as an act of terrorism, marks one of the deadliest single incidents for the energy company DTEK since the invasion began.
Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.
